[{"id":"1cf5d688-5325-4132-8563-bf21d97a76a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06106802","created_at":"2023-10-30T16:12:46.526Z","updated_at":"2024-07-02T16:35:31.209Z","phase":"Phase 2","brief_title":"Lazertinib \u0026 Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment","source_id_and_acronym":"NCT06106802","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR • BRAF • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR C797S • EGFR mutation + MET-CEP7 fusion","tags":["EGFR • BRAF • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR C797S • EGFR mutation + MET-CEP7 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tepmetko (tepotinib) • Lazcluze (lazertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/02/2024","start_date":" 02/02/2024","primary_txt":" Primary completion: 09/30/2029","primary_completion_date":" 09/30/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2023-10-30"},{"id":"a44fd9da-48a5-4030-9451-0e84dbc43d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05430386","created_at":"2022-06-24T15:56:28.883Z","updated_at":"2024-07-02T16:35:55.559Z","phase":"Phase 1","brief_title":"Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT05430386","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • MET mutation • MET positive • EGFR T790M negative • EGFR mutation + MET-CEP7 fusion • MET positive + EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib) • dalmelitinib (HS-10241)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-14"}]